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Abstract
Background: The xanthophyll carotenoids lutein (L) and zeaxanthin (Z) are found in and around the macula of the
primate retina, where they are termed macular pigment (MP). Dietary L and Z are absorbed with fat in the gut and
transported on lipoproteins to the retina. Both MP and serum lipoproteins have been related to risk for
neurodegenerative diseases such as age-related macular degeneration (AMD). L and Z are carried on both HDL
(related to reduced risk of AMD) and LDL (related to increased risk). The purpose of this set of studies was to
analyze the relation between L and Z in the serum and retina with the circulating lipid profile.
Methods: In all experiments, lipoproteins were measured enzymatically from plasma, and MP optical density
(MPOD) was measured using customized heterochromatic flicker photometry. Experiment 1: Relations between serum
L and Z, MPOD and lipoprotein levels. 108 young, healthy subjects (M = 23.2, SD = 4.12 years) participated.
Lipoprotein levels and MPOD were measured. In a subset of 66 participants, serum L and Z levels were also
measured using high-performance liquid chromatography. Experiment 2: Relations between lipoprotein levels and
MPOD in statin users. 20 subjects (M = 58.05, SD = 11.08 years) taking statin medication and 20 subjects (M = 57.95,
SD = 11.03 years) not taking satin were recruited for participation. MPOD and lipoprotein levels were measured.
Experiment 3: lowering lipoprotein levels to impact MPOD. One individual (aged 41 years) with high MP density
adhered first to an atorvastatin regimen, then, after a wash-out period, to a rosuvastatin regimen.
Results: Experiment 1: HDL were significantly (p < 0.05) related to MPOD (r = 0.33), to serum L (r = 0.36) and to
serum Z (r = 0.26). MPOD was also significantly related to total cholesterol (r = 0.19). Experiment 2: MPOD was not
lower in statin users when compared to matched non-statin users, but MPOD decreased significantly with
increased duration of statin use (r = −0.63). Experiment 3: Administration of a statin regimen reduced MPOD with
atorvastatin (p < 0.05) but not with rosuvastatin.
Conclusions: Serum xanthophylls, retinal xanthophylls and lipoprotein concentrations are significantly related, and
changing lipoprotein levels may impact levels of retinal xanthophylls.
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Background
Approximately 600-800 different carotenoids exist [1,2]
and serve a multitude of functions such as light harvesting
for plant photosynthesis and protection from free-radical
damage (for review, see [1-3]). Carotenoids cannot be
synthesized by the majority of animal species de novo and
must, consequently, be consumed in the diet. Of the 600-
800 carotenoids that have already been classified in nature,
only a small number (about 25) is found in commonly-
consumed foods [4] and, therefore, human serum. Carote-
noids in the body retain many of their original plant func-
tions, such as light absorption in the eye and in skin, and
singlet oxygen quenching in a variety of tissues. Carote-
noids can also improve cell membrane stability, alter tran-
scriptional activity, regulate immune function, reduce
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ing (e.g., [2,3,5-10]).
The majority of somatic tissues contain carotenoids,
and the majority of these tissues contain more than one
carotenoid. There are, however, some tissues that tend to
absorb one or two carotenoids to the exclusion of others.
For example, lutein (L) and zeaxanthin (Z) are found
alongside a number of other carotenoids (e.g., alpha-car-
otene, beta-carotene, beta-cryptoxanthin, lycopene) in
tissues such as liver, kidney and lung (e.g., [11]) but are
the only carotenoids found in the crystalline lens[12,13]
and macular region of the neural retina, where they and
their isomer meso-zeaxanthin (MZ) are termed macular
pigment (MP) (e.g., [14,15]). In the macula, L and Z are
thought to serve many of the above functions, and high
MP optical density (MPOD) has been linked to reduced
risk of age-related macular degeneration (AMD), an
acquired neurodegenerative disease and one of the
world’s leading causes of blindness [16-20]. AMD has
similar risk profiles to other neurodegenerative diseases,
such as Alzheimer’s disease (e.g., [21-23]), and to cardio-
vascular disease ([24-29]. Among those risk factors are
high plasma concentrations of low-density lipoproteins
(LDL) (e.g., [28,30-33], low concentrations of high-den-
sity lipoproteins (HDL) (e.g., [30,31,34,35]), elevated
plasma triglyceride concentrations (e.g., [29,30,32]), and
low serum L and Z levels (e.g., [36-42])
Dietary L and Z are absorbed with fats in the gut and
are eventually transported to the liver (e.g., [43]). L and Z
within the liver are incorporated into lipoprotein mole-
cules that are transported throughout the bloodstream as
part of a carotenoid-lipoprotein complex. The association
of individual carotenoids with the various lipid fractions
is relatively specific and is determined by the size and
hydrophilicity of the carotenoid. For example, pure
hydrocarbon carotenoids like beta-carotene and lycopene
are carried predominately on LDL fractions, which is lar-
gely the basis for the suggestion that they may play a pre-
ferential role in reducing LDL oxidation [44]. Other
carotenoids, such as the more hydrophilic xanthophylls,
show different patterns of transport. L, for example, is
carried preferentially on HDL (approx. 52%) and to a les-
s e re x t e n to nL D L( 2 2 % )[ 4 5 ] .P a s td a t ah a ss h o w nt h a t
circulating levels of L and Z are positively correlated with
both serum HDL and LDL fractions but not with VLDL
fractions [46].
Given the fact that carotenoids are bound to circulating
lipoproteins (and delivered to target tissues via this
mechanism), the relation between serum levels of the var-
ious lipoprotein and tissue concentrations of carotenoids
is of interest. Unlike other carotenoids, retinal L and Z
(i.e., MP) can be measured in situ and non-invasively
using psychophysical methods, such as heterochromatic
flicker photometry (HFP) (e.g., [47]). Consequently, it is
relatively easy to measure relationships between circulat-
ing lipoproteins, serum L and Z levels and MP density.
Given the fact that concentrations of both the carotenoid
and the lipoprotein carrier are related to risk for AMD (e.
g., [16,26,30,31,39]), Alzheimer’s disease (e.g., [36,37]) and
cardiovascular disease (e.g., [24-28,38,48]), it would be use-
ful to determine whether or not these sources of risk are
independent. For example, the question of whether HMG
Co-A reductase inhibitors (i.e., statins), increasingly widely
used, and which are known to reduce circulating lipopro-
tein levels, impact the amount of L and Z available to bind
to brain and retina has not been studied.
Past research that has addressed the relations between
plasma lipoproteins, serum L and Z and MPOD has been
conflicting and has largely not addressed the issue of sta-
tin use. For example, Broekmans et al [49] originally
measured MP using a reflectance method and related
those measures to serum carotenoids and plasma lipo-
protein concentrations in 376 subjects. Like past studies,
they found a positive relation between serum L and
plasma HDL and LDL fractions. They also found a nega-
tive relation between MP and serum triglycerides but no
relation between MPOD and HDL and LDL. These
results are interesting but difficult to interpret. For
instance, Broekmans et al [49] reported an average serum
L and Z level of about 0.23 μmol/L, which is 44% lower
than the average normative value reported by the large
sample (n = 7059) studied in the Third National Health
and Nutrition Examination Survey (NHANES III) (0.41
μmol/L) [50]. Broekmans and colleagues also report lipid
profiles that contrast with NHANES III norms (e.g., 23%
higher triglyceride levels compared to levels reported by
the National Cholesterol Education Program) [51] (16).
Approximately 32% of the sample were smokers and,
unlike other studies [52,53], MP density was not related
to smoking status in their sample. Taken together, the
sample and results reported by Broekmans et al. appear
to be different enough that their data probably should
not be regarded as sufficiently representative to make
their results conclusive.
More recently, Loane et al [54] investigated the rela-
tionship between serum L and Z, plasma lipoproteins
and MPOD. In contrast to Broekmans et al [49], Loane
and colleagues found that serum L and Z concentrations
were positively related to total cholesterol and HDL, and
inversely related to plasma triglyceride concentrations,
but not to LDL. No relationships, positive or inverse,
were seen between any of the lipoproteins tested and
MPOD. Given the conflicting nature of past research in
this area, we present a collection of three separate stu-
dies, conducted at different times with different samples,
that is designed to clarify the relationship between
plasma lipoprotein levels, serum L and Z and MPOD in
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levels (including statin users) across the lifespan.
Methods
General
Although each of these experiments was conducted at a
different time point, each experiment was approved by
the University of Georgia Institutional Review Board,
and the tenets of the Declaration of Helsinki were
adhered to at all times. All values below are expressed
as mean ± standard deviation.
Participants
Experiemnt 1: Relations between serum L and Z, MPOD and
lipoprotein levels
108 young, healthy subjects (44 males, 64 females; M =
23.20 ± 4.12 years) were recruited from the University
of Georgia student research participant pool as part of a
larger, ongoing study on the effects of lutein supplemen-
tation on visual function. Informed consent was issued
and all practices and procedures were approved by the
University of Georgia Institutional Review Board. All
participants were free of ocular disease, had best cor-
rected visual acuity of at least 20:40 or better (Snellen
notation), and reported no history of ocular disease. Par-
ticipants were given a medical examination by a quali-
fied physician prior to enrollment to ensure general
good health.
Experiment 2: Relations between lipoprotein levels and
MPOD in statin users
A total of 20 individuals who had been taking statin
medication for a period of at least four-months prior to
enrollment were recruited from the Athens, GA com-
munity. These participants (n = 13 males, 7 females, M
= 58.05 ± 11.08 years) were carefully matched with 20
healthy individuals not on statins (n = 14 males, 6
females, M = 57.95 ± 11.03 years) on a number of fac-
tors known to influence MPOD, such as BMI, smoking
s t a t u s ,p r e s e n c eo fT y p eI Id i a b e t e sa n dc a r o t e n o i d
intake. Prospective participants were screened by ques-
tionnaire and excluded on t h eb a s i so ft h ef o l l o w i n g
parameters: known diagnosis of HIV, use of blood-thin-
ning medications, confirmed diagnosis of sarcoma or
carcinoma within the last 5 years, use of chemotherapy
and immunosuppressive medications, visual acuity that
could not be corrected to 20/60 or better, and failure to
meet fasting requirements of 12 hours or more prior to
participation.
Experiment 3: case-study: lowering lipoprotein levels to
impact MPOD
One mildly hyperlipidemic (total cholesterol = 6.18
mmol/L, LDL = 4.15 mmol/L) subject (male, 41 years of
age) who was experienced in the psychophysical metho-
dology used in this study (described below) underwent a
low-dose (10 mg) atorvastatin (Lipitor
®, Pfizer Pharma-
ceuticals) intervention for one-month. The subject
otherwise met inclusion criteria listed for Experiment 2
above and maintained stable dietary and exercise habits
during the course of the study. Following a two-year
wash out period, the same subject began a one-month
regimen (10 mg) of rosuvastatin (Crestor
®,A s t r a Z e n c a
Pharmaceuticals). Although statin medications lower
cholesterol production via inhibition of HMG-CoA
reductase in the liver, lipophilic atorvastatin is, like its
counterparts simvastatin and lovastatin, known to cross
the blood-brain barrier, unlike hydrophilic rosuvastatin
and its counterparts fluvastatin and pravastatin [55].
Both lipophilic and hydrophilic statins were used to
ensure that any resulting changes in MP density were
due to lipid-lowering activities as opposed to any direct
neural influence of statins that cross the blood-brain
barrier or, by extension, the blood-retina barrier.
Materials and methods
Plasma lipoprotein concentrations
Experiment 1
Lipids were analyzed from the plasma samples sched-
uled for xanthophyll quantitation. LDL, HDL, choles-
terol and triglyceride levels were measured in
heparinized plasma using commercially available test
kits on a Roche-Hitachi Clinical Autoanalyzer. In brief,
for LDL and HDL analysis, the respectively bound cho-
lesterol is enzymatically cleaved and oxidized. This oxi-
dation leads to hydrogen peroxide as side-product,
which is quantified using a color reaction. For analysis
of triglycerides, glycerol is enzymatically freed using
lipases, followed by an oxidation leading to hydrogen
peroxide as side-product. This is quantified using a
color reaction and measured with photometry.
Experiments 2 and 3
In order to make lipoprotein analysis more convenient
for older adults and for repeated testing on the case
study, plasma total cholesterol, HDL, LDL and triglycer-
ide levels were assessed via the Cholestech LDX portable
lipid analyzer (Cholestech Corporation). Portable lipid
analyzers provide a reasonably accurate and convenient
way to screen participants for lipid status [56,57]. The
LDX is able to accurately measure lipid profiles when
samples are derived from whole blood, when a single,
trained operator performs lipid analysis, and when all
precautions are taken to avoid error during the collec-
tion phase (e.g., swabbing the finger with alcohol, col-
lecting while fingertips are warm, not ‘milking’ the
finger, etc.) [57]. Consequently, all whole blood samples
were collected under these conditions. To ensure proper
functioning of the LDX system, quality control was per-
formed periodically utilizing known internal standards
(Cholestech Corporation).
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Participants in Experiment 1 were, as stated previously,
recruited for a larger, ongoing study on lutein supple-
mentation and visual function. Serum was analyzed for
L and Z concentration in 66 of those 108 initially
recruited participants during phase I of the larger study.
For those 66 participants, L and Z levels were deter-
mined via high performance liquid chromatography
(HPLC), as described previously [58]. Briefly, L and Z
were extracted from the aqueous suspension with n-
hexane/chloroform. After centrifugation, an aliquot of
the organic phase was evaporated to dryness, re-dis-
solved in mobile phase and analyzed on a normal-phase
(Si-60) HPLC system. The detection is performed with a
UV/Vis detector at 452 nm for both xanthophylls. The
method is a standard one, which is regularly checked for
accuracy and precision by attending to inter-laboratory
studies organized by the National Institute of Standard
& Technologies (NIST) in the USA, and by the Societé
Francophone Vitamine & Biofacteurs (SFVB) in the Eur-
opean Union. To assess the daily and long-term labora-
tory performance of the HPLC plasma analytics,
dedicated control plasma is used. The control samples
are analyzed at least 4 times/day during the study.
Dietary assessment (Experiment 2 only)
Fruit and vegetable intake was measured via the com-
mercially available 7-Item Eating Habits Screener
© from
Block Dietary Data Systems. Burke et al [59] compared
the 7-Item Eating Habits Screener
© with the more com-
monly used Fred Hutchinson Cancer Research Center
Food Frequency Questionnaire (FFQ) and found that
both screeners compared well in their ability to categor-
ize dietary intakes of fruits and vegetables, including L
and Z-rich fruits and vegetables, into low, medium, high
and very high levels. Scores on both eating habits assess-
ments were also significantly correlated with MPOD,
tested at a central retinal locus (r =0 . 2 4 ,p = 0.02, n =
96 with the Fred Hutchinson FFQ; r = 0.27, p = 0.006, n
= 96 with the 7-Item Eating Habits Screener
©).
MPOD measurement (all experiments)
MPOD was measured psychophysically via customized
HFP (cHFP). The method for assessing MPOD via cHFP
has been previously described [47,60]. Briefly, the basic
measurement procedure involves presenting a small test
stimulus that alternates between a measuring wave-
length strongly absorbed by MP (460 nm) and a refer-
ence wavelength not absorbed by the pigments (550
nm). This stimulus is presented in the center of the
fovea and at an eccentric location (7 degrees), which is
used as a reference. In effect, the subject perceives a test
l i g h tt h a ta p p e a r st of l i c k e r .T h es u b j e c ti st h e n
instructed to adjust the intensity of the measuring light
until flicker is eliminated. The log difference in the mea-
surement and reference values yields a measure of MP
optical density at the test locus. HFP is one of the most
widely used and highly validated psychophysical techni-
ques for assessing MP density (e.g., [61]). The denota-
tion of “customized” HFP refers to an ability to optimize
viewing conditions (e.g., low-frequency flicker rates) for
each subject and has been validated in a wide variety of
subjects.
Results
All statistics were computed utilizing Microcal Origin,
version 8.1, and SPSS, version 18.0 (p ≤ 0.05 defined
significance).
Experiment 1. Relations between serum L and Z, MPOD
and lipoprotein levels
Descriptive statistics for all of the major dependent
measures are shown in Table 1. A Pearson product-
moment correlation matrix was constructed to describe
the relation between lipoproteins, serum L and Z,
MPOD and BMI (see Table 2). As shown in the table,
MP was positively related to HDL (r =0 . 3 3 ,p < 0.01)
and total cholesterol (r =0 . 1 9 ,p < 0.05). MP did not
significantly relate to any of the other lipoproteins, or to
BMI. Serum L was marginally related to total cholesterol
(r = 0.21, p < 0.09) and was significantly related to HDL
(r = 0.36, p < 0.01). Serum Z was not related to total
cholesterol but was significantly related to HDL (r =
0.26, p < 0.05). These analyses controlled for age and
sex.
Experiment 2. Relations between lipoprotein levels and
MPOD in statin users
In order to determine whether statin-users and non-
users were well-matched, a one-way ANOVA was con-
ducted on all matching parameters that were on the
interval or ratio scales of measurement (see Table 3).
No significant differences were seen between statin-
users and non-users (p ≥ 0.05), indicating that the
matching procedure was successful. To determine that
lipid status was different between statin-users and non-
users, a series of independent samples t-tests were per-
formed, using the Bonferroni procedure to control for
family-wise error. Non-users showed significantly higher
total cholesterol (t = −3.09, p ≤ 0.05), LDL cholesterol (t
= −3.37, p ≤ 0.05) and LDL:HDL ratios (t = −2.05, p ≤
0.05) compared with statin-users. Consequently, we can
state with some confidence that serum lipid status dif-
fered between the two groups, but other potentially con-
founding factors (e.g., BMI, smoking status, presence of
Type II diabetes) were similar.
A comparison of MP density between statin-users and
non-users showed that MP density was not significantly
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0.05). After excluding individuals with Type II diabetes
from the analysis, MP density was still not significantly
different between statin users and non-users (p ≥ 0.05).
However, a significant inverse correlation between dura-
tion of statin use and MP was found at all eccentricities
tested (r = −0.613, r = −0.442, r = −0.499, r = −0.685
for 10-minutes, 15-minutes, one-degree and two-
degrees, respectively) (p ≤ 0.05), after controlling for age
and presence of type II diabetes. An example of one of
these relations is shown in Figure 1.
Experiment 3. Case-study: lowering lipoprotein levels to
impact MPOD
Baseline, intervention and post-supplementation
averages for the case study participant during both the
atorvastatin intervention and the rosuvastatin interven-
tion are shown in Table 4. Differences between MP den-
sity and serum lipids were assessed via one-way
ANOVA with correction via the Bonferroni procedure
to control for multiple comparisons. During the atorvas-
tatin intervention, total cholesterol and LDL cholesterol
dropped significantly from baseline (p ≤ 0.01) and
remained low post-intervention (p ≤ 0.05). In addition,
TC:HDL and LDL:HDL ratios were significantly lower
during the atorvastatin intervention and post-interven-
tion compared with baseline (p ≤ 0.05). MP density
decreased significantly at the most peripheral locus
(1.75-degrees) by about 60% during the intervention (p
≤ 0.05). MP density rebounded to original levels post-
intervention. MP density decreased slightly but not sig-
nificantly at other loci in the spatial profile during the
intervention (See Table 4, Figure 2).
During the rosuvastatin intervention, total cholesterol
was significantly lower during the intervention when
compared with pre- and post-intervention periods (p ≤
0.05). Specific lipid fractions (i.e., HDL and LDL), did
not differ significantly when compared independently of
the total cholesterol value (p ≥ 0.05). MP density did
not change significantly during the rosuvastatin inter-
vention (See Table 4, Figure 3).
Discussion
The results of Experiment 1 suggest that MP is related
to HDL but not the other lipoprotein fractions. This
result is inconsistent with results from both Loane et al
[54], who report no relation between MPOD and lipo-
proteins, and Broekmans et al [49], who report a signifi-
cant difference between plasma triglycerides and MP.
There are some noteworthy differences between these
Table 1 Descriptive statistics for participants enrolled in Experiment 1 (n = 108)
Variable Mean Standard Deviation Range Minimum Value MaximumValue
Age (years) 23.22 4.11 23.00 18.00 41.00
BMI 23.20 2.67 13.10 19.50 32.60
30-minute MPOD 0.44 0.17 0.89 0.02 0.91
Total cholesterol (mmol/L) 4.42 1.01 5.52 2.77 8.29
HDL (mmol/L) 1.47 0.38 2.05 0.70 2.75
Triglycerides (mmol/L) 1.17 0.68 4.51 0.36 4.87
LDL (mmol/L) 2.43 0.80 4.25 0.98 5.23
Lutein (μmol/L) 0.19 0.10 0.44 0.05 0.49
Zeaxanthin (μmol/L) 0.07 0.03 0.17 0.01 0.18
Table 2 Pearson-product moment correlation coefficients between the dependent measures in Experiment 1 (n = 108)
MPOD Body Mass Index Total Cholesterol HDL LDL Triglycerides Serum L Serum Z
MPOD 1 -0.10 0.19* 0.33** 0.11 -0.14 0.31* 0.21†
Body Mass Index 1 -0.05 -0.00 -0.04 -0.04 -0.07 -0.02
Total Cholesterol 1 0.42** 0.90** 0.41** 0.21† 0.05
HDL 1 0.12 -0.20* 0.36** 0.26*
LDL 1 0.29** 0.10 -0.03
Triglycerides 1 -0.01 -0.12
Serum L 1 0.79**
Serum Z 1
Note: MPOD assessed at 30-min of eccentricity
** = p ≤ 0.01, two-tailed
*=p ≤ 0.05, two-tailed
† = p ≤ 0.09, two-tailed
Renzi et al. Lipids in Health and Disease 2012, 11:33
http://www.lipidworld.com/content/11/1/33
Page 5 of 10studies that may account for inconsistencies in results.
For example, Broekmans and colleagues tested a larger
number of subjects (n = 376), and the relation they
report is quite small (r
2 = 0.03). The magnitude of the
relationship in our study was similar but the sample was
smaller and therefore there was not enough statistical
power to reach significance. Also, we screened our sam-
ple for conditions that could affect L absorption (e.g.,
smoking and medical history). Broekmans et al also
used different methods to test MP density that could
have created a restricted range in their MP data (for
review of methodological concerns for MP measure-
ment, see [61]). Hence, it is likely that the differences in
study population and methodology account for the dif-
ferences between our results and those of Broekmans
et al. Our results suggest that there is a significant and
positive association between serum L and Z, MP and
HDL. This finding is consistent with a presumed
mechanism of L and Z delivery to the retina. L and Z
a s s o c i a t em o r ec l o s e l yw i t hH D La n dT h o m s o ne ta l .
(2002)[62] have suggested that a small proportion (2.5%)
of HDL might be responsible for transporting L and Z
to the retina (with little or no role for the other lipids).
Additional evidence for HDL as the major carrier for L
has been provided by Connor et al [63], using WHAM
chicks, which are HDL deficient.
The relation between MP and lipid-lowering medica-
tions appears to be less straightforward. For example, MP
density was not significantly different between statin-users
and non-users, despite the fact that lipid levels were higher
Table 3 Matching parameters for Experiment 2 (n = 40).
Group Age (years) Gender Iris Color* BMI (kg/m
2) Carotenoid Intake Score Smoking Status Years Smoking
Statin
Users
58.05 ± 11.08 n = 13 males
n = 7 females
2.1 ± 0.9 27.51 ± 5.19 14.1 ± 5.25 n = 13 nonsmokers
n = 7 past smokers
n = 0 current smokers
5.3 ± 9.18
Non-Users 57.95 ± 11.03 n = 14 males
n = 6 females
1.9 ± 0.8 26.34 ± 2.73 13.93 ± 3.63 n = 12 nonsmokers
n = 4 past smokers
n = 4 current smokers
9.10 ± 12.47
Values expressed as mean ± SD unless otherwise indicated
*1 = dark irides, 2 = green/hazel irides, 3 = blue/gray irides
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Figure 1 Decline in MPOD with increased duration of Statin use for participants in Experiment 2; r = −0.613, p ≤ 0.05. Note that all 20
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confined to statin-users, longer-term statin use was related
to reduced MP density. Given the fact that Experiment 2
used a case-control design instead of a longitudinal design,
data on MP changes throughout each subject’ss t a t i n
regimen were unavailable. This result is, however, consis-
tent with data from our case-study, in which MP density
was assessed throughout the intervention. As shown in
Figures 2 and 3, the case study participant showed a
reduction in MP density in the more peripheral regions of
Table 4 Baseline, intervention and post-intervention lipid concentrations and MP densities for case study participant
Phase 15-min MP
density
30-min MP
density
1-deg MP
density
1.75-deg MP
density
TC
(mmol/
L)
HDL
(mmol/L)
LDL
(mmol/L)
TC:HDL
(mmol/L)
LDL:HDL
(mmol/L)
AS Baseline 0.834 0.65 0.37 0.17 5.85 ±
0.33
1.27 ±
0.12
4.15 ±
0.26
4.64 3.29
AS
intervention
0.843 0.59 0.35 0.07 3.86 ±
0.35
1.39 ±
0.06
2.08 ±
0.45
2.8 1.50
AS post-
intervention
0.84 0.65 0.38 0.17 4.45 ±
0.25
1.37 ±
0.10
2.65 ±
0.24
3.28 1.94
Two-year wash-out period
RS Baseline 0.956 0.728 0.408 0.17 4.71 ±
0.56
1.31 ±
0.12
2.90 ±
0.69
3.62 2.25
RS
intervention
1.005 0.77 0.485 0.20 3.60 ±
0.31
1.43 ±
0.13
1.91 ±
0.34
2.65 1.35
RS post-
intervention
1.06 0.72 0.51 0.26 4.95 ±
0.0
1.22 ± 0.0 3.42 ± 0.0 4.1 2.80
AS = atorvastatin; RS = rosuvastatin
Values expressed as means ± SD
*given the fact that there were no significant differences in MP density during the intervention, only one post-intervention was taken
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Figure 2 Spatial profile for MP density in one, well-practiced subject before, during and after intervention with 10 mg atorvastatin.
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This effect was only found for the lipophilic atorvastatin
and not the hydrophilic rosuvastatin. Of course, the results
from one subject are obviously only suggestive and
whether the result would generalize is not known. Small
effects were noticeable with this particular subject, how-
ever, because the subject was extremely well-practiced in
the psychophysical task and did not change dietary habits
from baseline to intervention within the rosuvastatin and
atorvastatin conditions (which were separated by two
years). These preliminary data suggest that more research
is needed on the question of whether there are differences
between rosuvastatin and atorvstatin on retinal health and
whether long-term statin-use influences the retinal carote-
noids. If stain use does lower MP density over time, it
might be advisable to combine medication use with
increased intake of carotenoid-rich foods or L and Z sup-
plements. Vishwanathan et al [64] suggest that supple-
mentation with egg yolk, for example, is capable of
increasing MPOD in statin users with low MPOD at
baseline.
The finding that gross concentrations of serum HDL
and total cholesterol are related to MP is important. Poor
lipid profiles and low MP levels may pose an increased
risk for AMD (as well as other degenerative conditions)
(e.g., [16,17,31]). Statins could reduce sclerotic processes
within the eye that occur due to high cholesterol levels
(e.g., thickening of sclera and Bruch’s membrane) and
reduce inflammatory processes. L and Z have also been
shown to reduce inflammatory processes within the eye
[e.g., Izumi-Nagi et al. [7]] and retard atherosclerosis (e.
g., Dwyer et al., 2001 [57]). Managing intake of these
compounds could help to aggregate their health effects as
opposed to one partially offsetting the other.
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